Saxenburgh Medisch Centrum | Cardiology Department
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Participants must be at least 40 years old at the time of signing the informed consent.
Participants with Lp(a) ≥175 nmol/L at screening, measured at the central laboratory
Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to screening and randomization and expected to remain on a stable regimen through the end of the Treatment and Assessment Period:
Male and/or Female
Exclusion criteria
Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.
Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:
Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes.
Have uncontrolled hypertension
Primary purpose
Allocation
Interventional model
Masking
216 participants in 5 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal